Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat
Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityAuthor: Thomas Hughes. Posted: 4/23/2026. 
Key Points
- Instuitive Surgical hit bottom in early 2026 and is set up to rebound robustly.
- Accelerting device placement, procedure volume, and consumable supplies underpin the growth outlook.
- Competition exists but trails significantly, leaving this company with a wide moat.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its high valuation and slowing growth. That combination has weighed on price action since early 2025 and is unlikely to disappear overnight. Still, the current rich valuation already prices in solid growth, which may understate the company’s long-term potential. Intuitive Surgical’s potential lies in its dominance of robotic surgical procedures. The company has a first-mover advantage, with an installed base of more than 12,000 devices and growing. In that context, a 45X valuation on current-year earnings is only a modest hurdle relative to the potential for a 50% or greater increase in the stock over the next few years.
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
And that assumes the long-term forecasts are accurate. To date, Intuitive Surgical has consistently outperformed expectations, and device deployments and procedure volumes continue to expand. The more likely scenario is that ISRG continues to outperform and sparks a bullish revision cycle over the long term. Market Overreaction Sets Up ISRG OpportunityAnalysts played a role in ISRG’s stock decline in 2026. Leading into the fiscal Q1 2026 release there were downward price-target revisions, but the market overreacted, creating what looks like a deep-value opportunity. The revision trend leaves a consensus price target that implies more than 30% upside from critical support levels, and conviction in that forecast is high. MarketBeat tracks 25 analysts; the consensus rating is Moderate Buy, with a 68% buy-side bias reflected in institutional activity. The institutional activity is revealing. Institutions own more than 80% of the stock and have been accumulating throughout the corrective period. Their activity increased into Q1 2026 and remained strong in the first weeks of Q2. The trailing 12-month balance is nearly 2-to-1 in favor of buyers, with Q1 and Q2 activity reflecting accelerating demand. The takeaway is that ISRG has a solid floor in the $445-to-$450 region and is positioned for a robust rebound in Q2 and later in 2026. Stock price action mirrors the institutional flows: declines stalled near $445 and were followed by rebounds. The mid-Q2 setup favors a rebound, with the market establishing support at that critical level and advancing after the Q1 release. Indicators such as the MACD and the stochastic oscillator are also aligned, suggesting a trend-following move that could lift the stock back toward record highs. Technical hurdles include the long-term 150-day exponential moving average near $500 and resistance around prior peaks near $560 and $600. Buybacks Add Leverage: Underpin Stock Price OutlookBuybacks are another reason ISRG could reach new highs. Not only is the company outperforming and forward estimates improving, but share repurchases have improved shareholder leverage. The Q1 release shows more than $1.1 billion in quarterly repurchases, reducing the share count by roughly 0.15% sequentially and about 1.3% year over year, and the company retains capacity to continue buying shares at a meaningful pace. Intuitive Surgical’s balance sheet reflects the impact of buybacks and acquisitions, but these are offset by strong cash flow and the shareholder leverage gained. The company shows reduced cash balanced by lower liabilities and relatively steady equity. In this position, ISRG can continue repurchasing shares while maintaining balance sheet health, including a zero-debt balance. As it stands, Intuitive Surgical is net cash relative to total liabilities, with cash exceeding liabilities by more than 3.15X — arguably one of the stronger balance sheets on Wall Street. Intuitive Surgical’s Q1 Release Triggers Market ReboundIntuitive Surgical reported a robust Q1, reaffirming trends and suggesting forward estimates may be conservative. Net revenue of $2.77 billion was up 23.1% year over year, beating consensus by roughly 550 basis points. Growth was driven by device placements (up 17%), procedure volume (up 17%), and instrument sales (up 23%). The installed base grew 12%, pointing to continued gains in upcoming quarters, and margins improved. Adjusted net income grew 36%, outpacing topline growth by more than 1,300 basis points, and management expects profitability to remain strong in coming quarters. Guidance calls for full-year Da Vinci device growth of approximately 14.5%, with procedure and instrument sales following a similar trajectory. The biggest risk for the company, aside from valuation, is competition, but rivals remain well behind. The closest is Medtronic’s (NYSE: MDT) Hugo system, which has seen traction in overseas markets but is still in early rollout stages. Catalysts for ISRG include the early adoption of the Da Vinci 5, AI-related opportunities, and international expansion. Japan, specifically, recently approved seven new robotic procedures and is viewed as a notable growth driver. |
Post a Comment
Post a Comment